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ABSTRACT
This study reports the release properties of the poorly water-soluble drug hydrocortisone, antibacterial agent triclosan, and the
water-soluble anti-aging compounds salicylic acid and ascorbic acid from gels, creams, and ointments, alone or combined with
triclosan. Drug release was measured with the flow-through, Franz, and Enhancer cell release testing methods. For the 3 methods, a
cellulose acetate membrane soaked in lipophilic oleic acid and dissolution mediums composed of a phosphate buffer pH 5.8 or a 50%
ethanol: buffer mixture gave more constant and less variable release profiles (similarity factors, f2, above 50). Comparison of the
release rates of hydrocortisone, salicylic acid, ascorbic acid, and triclosan from creams and gels showed that the rates measured with the
flow-through cells were significantly slower (p < 0.01) than those measured with the Franz and Enhancer cells. In all 3 systems,
hydrophilic compounds released faster in the buffer solution and from the gels. Less water-soluble compounds and lipophilic
compounds released faster in the hydro-alcohol mixture and from creams and ointments. The disadvantages of the flow-through cells
were difficult operation and small sample sizes which caused variable results. The advantages of the Enhancer cells were that they used
the basic USP dissolution apparatus and had a larger volume range making it easier to adapt the system for studying the release of
products containing low concentrations of active ingredients or ingredients that are difficult to analyze.
Key words: cosmeceutical, semisolids, release, dissolution, Franz cell, Enhancer cell, flow-through cell

INTRODUCTION
The term cosmeceutical is a blend of cosmetic and
pharmaceutical and refers to products which are marketed
as cosmetics, but which contain biologically active ingredients that affect the structure or function of the skin, hair or
nails. The term was coined by Albert Kligman, the
University of Pennsylvania researcher credited with discovering the effectiveness of Retin-A, a vitamin A, in
smoothing aging skins. Other examples of cosmeceuticals
are anti-wrinkle creams, acne-treatments, baldness treatments, moisturizers, and sunscreens, which contain ingredients such as vitamin E, ascorbic acid, etc. These products
are causing problems worldwide for regulatory authorities,
such as the U. S. Food and Drug Administration (FDA),
which must decide when a product crosses the line between
being merely a cosmetic and becoming a drug, the latter
having much more stringent controls on its development,
testing and supply. For pharmaceutical products, the
typical semisolid dosage form quality control tests include
identification, assay, homogeneity, viscosity, particle size,
and release (dissolution) testing.
* Author for correspondence. Tel: + 318-342-1727;
Fax: + 318-342-1737; E-mail: devilliers@ulm.edu

Historically, although in vitro release rate testing from
semisolids could potentially provide valuable information
about product performance but it is not an industry wide
quality control test requirement as compared to the utility of
in vitro dissolution testing of oral dosage forms (1). To
change this situation the extension of in vitro dissolution
methodology to semisolid dosage forms has been the subject
of substantial effort and debate(2,3,4). Similar to the dissolution testing of oral dosage forms, a simple, reliable and
reproducible release rate method can guide formulation
development; help to monitor batch-to-batch quality and stability, and control the manufacturing process of cosmeceuticals. It is particularly useful for detecting the effect of product changes including drug substance, excipients, and manufacturing process. This has led to the establishment of the
FDA SUPAC-SS guidance requiring the performance of
release testing from semisolid dosage forms after certain
post approval changes(5). In particular, in vitro dissolution
of the pre- and post change formulations must be compared
whenever changes are made to the product’s composition,
manufacturing equipment, or process (5) . This in vitro
release requirement is not surrogate for in vivo bioequivalency testing, but is intended to assess “sameness” of a product
following scale-up or post-approval manufacturing changes.
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Although the FDA SUPAC-SS guidance include
general methodology descriptions of diffusion systems, it
does not specify a particular test methodology because
currently no compendial in vitro release test methodology is
described for semisolid dosage forms (1,5) Compendial
transdermal dosage form release methods include the
paddle over disk (apparatus 5), cylinder (apparatus 6), and
reciprocating disk (apparatus 7) described in the United
States Pharmacopeia(6). Recently a significant amount of
effort, research, innovation, and debate has surrounded the
topic of in vitro dissolution methodology for semisolid
dosage forms(7,8). From these reports, it is clear that a wide
variety of diffusional systems have been utilized and that
the current dissolution testing systems for semisolid dosage
forms originated from systems used for in vitro skin permeation studies(7).
Among these methods, the Franz diffusion cell, Figure
1 (A), has been the standard system used for the study of
semisolid drug formulations(9,10,11). First described by
Franz in 1978(12), this cell has a small donor compartment
and a cylindrical receptor chamber that allows mixing with
a magnetic stir-bar. As an alternative to the Franz-type in
(A)

vitro dissolution testing system the Enhancer Cell, Figure 1
(B), was introduced commercially in the early 1990’s by
VanKel Industries(7,8). The system consists of a donor
chamber (the cell body) for the dosage form that is covered
by a synthetic membrane. The entire assembly is placed in
the bottom of a standard USP Apparatus 2 dissolution
vessel. A third system that is increasingly used for
measuring the release rate of drugs from semisolid dosage
forms is a modified version of the flow-through apparatus
(USP apparatus 4)(13,14). For measuring the release of drug
from semisolid dosage forms, an ‘insertion cell’, Figure 1
(C), is placed inside the flow-through cell. The insertion
cell offers the advantage that it is readily adaptable for use
with the compendial flow-through apparatus and does not
suffer from the problem of having to remove air bubbles at
the membrane/liquid interface, which commonly occurs
when using Franz cells(14).
Although these three methods are used for testing
pharmaceutical products, their application for testing cosmeceuticals has not been reported. For pharmaceutical
products results obtained by the Franz cell and the
Enhancer cell systems have been compared and it is
(C)
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Figure 1. Schematic representations of (A) Franz, (B) Enhancer and (C) flow-through cell dissolution apparatuses.
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generally accepted that once the data is corrected for
differing surface area, drug release is nearly superimposable(7,8). However, reports describing comparisons
between the 3 methods for products containing compounds
with large differences in solubility and multiple active
ingredients are not available. This article reports the
release properties of the poorly water-soluble drug hydrocortisone and antibacterial agent triclosan, and the watersoluble anti-aging compounds salicylic acid and ascorbic
acid from gels, creams, and ointments, alone or combined
with triclosan, measured with the flow-through, Franz, and
Enhancer cell dissolution testing methods.

MATERIALS AND METHODS
I. Materials
Two semisolid products containing hydrocortisone
acetate Procutan ® (1.0% cream and ointment) and
Cutaderm (0.5% cream and ointment) were obtained from
Scherag Pty. Ltd., Johannesburg, South Africa. The active
ingredients incorporated into the anti-aging and acne gels
and creams were salicylic acid (Spectrum Chemical Co.,
USA), triclosan (Irgasan DP 300, Ciba Specialty
Chemicals, Basel, Switzerland), and ascorbic acid (Sigma,
USA). The excipients used in preparing the gels and
creams were ethyl alcohol, propylene glycol (Eastman
Chemical Co., USA), Carbopol 934 (BF Goodrich Co.,
USA), triethanolamine (J.T. Baker Chemical Co., USA),
isopropyl myristate, cetearyl octanoate (Croda, USA), cetyl
alcohol (Ruger Chemical Co., USA), stearic acid, liquid
paraffin, propyl 4-hydroxy benzoate, and methyl 4-hydroxy
benzoate (Sigma, USA). Reference standards for analysis
and chemicals used to prepare media for release studies
were obtained from Sigma Chemical Company (St. Louis,
USA) and were used as received.
II. Formulation of Creams and Gels
The gels and creams tested in the study were prepared
in small batches of 50-100 g, packaged in glass containers,
and kept at 5˚C throughout the study. The gels were
prepared as follows: Carbopol was slowly added to the
ethanolic solution containing salicylic acid, ascorbic acid,
or triclosan in a porcelain dish while being stirred with a
glass rod continuously. Next, propylene glycol was added
drop wise with continuous stirring. The products were kept
aside for 30 min and then triethanolamine solution was
added slowly until the gel was formed. The creams were
prepared as follows: Isopropyl myristate, cetearyl
octanoate, cetyl alcohol, stearic acid, liquid paraffin,
dimethyl polysiloxane, and glycerol monostearate were
mixed together and heated slowly until it liquefies.
Propylene glycol, methyl 4-hydroxy benzoate, propyl 4hydroxy benzoate and water were mixed together, heated
and added to the first mixture. The cream was then allowed

to cool down. The salicylic acid (0.5, 1, 2 and 3%),
ascorbic acid (6%), or triclosan (0.1, 0.5 and 1%) was
dissolved in either the oil or the water phase depending on
its solubility.
III. In Vitro Release Methods
As stated in the introduction, nearly all of the
published work on in vitro release from semisolids used
vertical Franz-type cells, Figure 1 (A). The system used in
this study consisted of 6 cells each with a polyethylene
sample ring with a 1 cm diameter hole at the centre, the
same size as the opening in the vertical receptor cells,
which is placed on top of the membrane and then filled
with the semisolid. The membrane with the sample was
placed on top of the vertical receptor cell and clamped
tightly into place. The receptor cells were filled with the
dissolution medium and a small magnetic stirrer placed in
each cell was used for mixing.
The Enhancer cell used in this study consisted of a
metal load ring, a cap, a membrane or skin, and a drug
reservoir, Figure 1 (B). The ointment or semisolid preparation was placed in the drug reservoir (2 cm diameter) on
top of the membrane or excised skin. A metal load ring
was used to keep the membrane or skin and the washer in
place during the cap application. Finally, the bottom screw
was tightened to bring the ointment, or semisolid preparation, in complete contact with the membrane or skin
making certain that no entrapped air is present at the
interface of the ointment, or semisolid preparation, and the
membrane or skin. A USP Six Spindle Dissolution Tester
(Vanderkamp 600, Van Kel Industries, NJ, USA) with
modified flask assemblies consisting of 200 mL flasks
instead of the standard 900 mL and smaller sized paddles,
was used to measure drug release from the enhancer cell
assembly. The paddles were rotated at 100 rpm.
Although the specified official use of flow-through
methods is not for semisolid dosage forms, their utility for
assessing release rates of drugs from semisolid dosage
forms has become a topic of considerable interest(13,14). In
this study a custom-made ‘insertion cell’ was constructed
Figure 1 (C), such that its dimensions permitted this cell to
be used with the compendial flow-through cell (USP 4
apparatus, SOTAX CE 70, Sotax, Basel, Switzerland). The
upper section of the ‘insertion cell’ consisted of an oblong
block of Plexiglas with a small circular hole (9 mm
diameter) cut through the middle and dimensions such that
it fitted into the flow-through cell. The middle section
consisted of a matching oblong block of Plexiglas with a 9
mm hole that acted as the sample holder. The lower part
was a solid block of Plexiglas of compatible dimensions.
All 3 sections were screwed together with the aid of 2 bolts
on both side of the 3 components. The membrane was
placed between the upper part and sample holder sections
prior to assembly. A stainless steel spring support was constructed to act as a holder for the ‘insertion cell’ when used
in the ‘turbulent flow’ mode, whilst a layer of glass beads
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(1 mm diameter) placed into the conical section of the
flow-through cell acted as a support for the ‘insertion cell’
when used in the ‘laminar flow’ mode.
Throughout this study, turbulent flow with the
insertion cell positioned at a distance of 10 mm from the
conical section of the flow-through cell and orientated
down was used to yield the maximum cumulative release.
This means that the membrane area was in direct contact
with the flow direction. The flow rate was 6 mL/min at a
constant temperature of 32˚C and samples (30 mL) were
collected in a Sotax C 615 fraction collector at 30 min
intervals. The Sotax CE 70 unit controlled the entire
system.
The membranes used in this study were either a silicon
gel sheet (Silastic ® medical grade sheeting, 0.01 mm
thickness, Dow Chemical Company, USA) sandwiched
between two cellulose acetate membranes (Osmonics Inc.,
USA) or only cellulose acetate with a pore size of 0.45 µm
soaked in 15% oleic acid in isopropyl myristate. The trilaminar membrane was tested in all three apparatus because
Yeung et al.(15) found that for water permeation the values
obtained for flux (402 µg/cm2/hr) and permeability coefficient (6.38 ¥ 10-3 cm/hr) were almost identical to those
obtained for excised human skin (409 µg/cm2/hr and 6.36 ¥
10-3 cm/hr). Previously reported release studies generally
prescribe the use of single or double cellulose acetate
membranes.
For all 3 methods the temperature was controlled at a
constant of 32˚C and exact volume samples were
withdrawn at 0.5 to 1 hr intervals from each flask up to 6
hr. For the Franz and Enhancer cell methods the volume
withdrawn were replaced with an identical volume of fresh
medium. A correction factor was included in the calculations to account for the drug loss during sampling. For each
sample a set of 6 diffusions were run to obtain cumulative
release profiles. The receptor mediums chosen were buffer
pH 5.8 and a ethanol/water mixtures. A pH of 5.8 was
chosen because the skin is reported to have a slightly acidic
pH(4-6) due to secretions from sweat glands, skin oil, and
the breakdown of fatty acids by Staphylococcus in the
epidermis(15).
IV. Analysis Methods
The HPLC methods used in this study complied with
specifications for precision, accuracy, selectivity, linearity,
and ruggedness as required by the USP XXIV (6). The
analysis of salicylic acid was carried out using an
automated high performance liquid chromatograph (Thermo
Separation Products, CA, USA) with a UV detector set at
265 nm. Salicylic acid eluted on a Discovery RP C16
HPLC column (250 mm ¥ 4.6 mm, 5 µm, Phenomenex,
USA) after 13 min with a mobile phase of water/methanol/
glacial acetic acid (60/40/1); flow rate 1.0 mL/min;
injection volume 20 µL.
The ascorbic acid was analyzed using a C18 column
(Macherey-Nagel Lichrospher RP18 5 µm, 250 ¥ 4 mm,

Germany). The apparatus was a Hewlett-Packard 1100
(Agilent Technologies, CA, USA) with a detection wavelength of 254 nm. The mobile phase was methanol/H2O/
glacial acetic acid/Triethanolamine (70/900/25/5). The
above-mentioned ratio contained 0.005M sodium heptane
sulphonate are and 150 mg of EDTA. The final pH was
3.6. A flow rate of 1.0 mL/min was used and the retention
time was 5 min.
For the analysis of triclosan the following reagents and
equipment were used: Hewlett Packard 1050 HPLC
(Agilent Technologies, CA, USA) equipped with a variable
wavelength UV detector, pump, injection device and computerized data analysis system; Luna C18 column (2 µm,
150 ¥ 4.6 mm) from Phenomenex, CA, USA controlled at
±20˚C; mobile phase was a mixture of methanol/water
(85/15) containing 0.1% H3PO4; flow rate 1.0 mL/min;
injection volume 10 µL; UV-detection at 210 nm; retention
time of 6 min.
Analysis of hydrocortisone acetate was also by means
of HPLC according to the method described in the USP
XXIV(6) using a Hewlett Packard 1050 HPLC (Agilent
Technologies, CA, USA), a Luna C18 column (2 µm, 150 ¥
4.6 mm, Phenomenex, CA, USA); mobile phase was a
mixture of methanol/water (60/40); flow rate 1.0 mL/min;
injection volume 10 µL; UV-detection at 254 nm; retention
time of 10 min.
V. Statistical Analysis
In vitro dissolution data from gels and creams was
compared by calculating similarity factors. Among several
methods used for dissolution profile comparison, the mathematical model using a similarity factor proposed by Moore
and Flanner(16) is the most popular and is recommended in
FDA guidance documents(5). The similarity factor between
two dissolution profiles is calculated by:
-0.5
¸
ÏÈ
n
1
˘
f2 = 50 ¥ log ÌÍ1 + Ê ˆ ¥ Â t =1 ( Rt - Tt )2 ˙ ¥ 100 ˝ Eq. 1
Ë n¯
˚
˛
ÓÎ
Where R t and T t are the cumulative percentage
dissolved at each of the selected time points (n) of the
reference and test products respectively. A f 2 value
between 50 and 100 ensures sameness or equivalence of the
two curves and thus the performance of the two products.
Statistical analysis was performed using SPSS 10.0 for
Windows (SPSS Inc., IL, USA). A 99% confidence level
(p < 0.01) was considered satisfactory for indicating significant differences. The mean values of the release rates were
compared for significant differences using one-way or twoway analysis of variance (ANOVA) for single factor and
two factor comparisons respectively.

RESULTS AND DISCUSSION
As a first step, the suitability of the HPLC analytical
methods for the active ingredients was determined. Figure
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2 shows representative HPLC chromatograms of the active
ingredients. With the aid of these methods, the release rates
of the active ingredients from creams, ointments, or gels
were measured with the 3 release testing methods.
Throughout the study, the release of the compounds was
linear when the amount released per square centimeter was
plotted as a function of the square root of time, in accordance with Higuchi’s model (r2 > 0.9). From these plots,
the release rate (flux, µg/cm2/min0.5) was calculated and
used to compare results. The similarity of release profiles
was also estimated from f2 values calculated using equation
1 and p < 0.01 was considered satisfactory for indicating
significant differences between release rates.

USP 24)(6) or mixtures containing the buffer and 30-50%
ethanol. Mean release rates are listed in Table 1 and 2.
As expected, the release of the more hydrophilic
salicylic acid was faster in the aqueous buffer pH 5.8 while
the release of the lipophilic triclosan tended to be faster in
media that contained 40-50% ethanol. The release rates
Hydrocortisone acetate
Salicylic acid

Ascorbic Acid
Triclosan

I. Selection of Conditions for In Vitro Release Testing
To determine the optimum experimental conditions for
comparing the release of the compounds measured with the
three diffusion apparatus, the release of salicylic acid and
triclosan from creams or gels was determined in different
media through cellulose acetate, cellulose acetate soaked in
15% oleic acid, or silicon gel sheet sandwiched between
two cellulose acetate membranes. For the purpose of this
comparison, salicylic acid represents a hydrophilic and
triclosan a lipophilic compound. The media tested were a
phosphate buffer pH 5.8 (0.2 M KH2PO4 and 0.2 M NaOH,

0

3

6

9

12

15

Time (min)

Figure 2. HPLC chromatograms of the active ingredients.

Table 1. The effect of a change in receptor medium composition and membrane on the release rate of salicylic acid from a 1% gel or cream
measured with the Franz, enhancer or flow-through diffusion apparatus
Method
Dosage Form
Membranea
Medium
Franz
Enhancer
Flow-through
(µg/cm2/min0.5)
(µg/cm2/min0.5)
(µg/cm2/min0.5)
Gel
CA
pH 5.8
259.08 ± 7.15
252.01 ± 9.08
217.92 ± 7.64
30% EtOH
231.34 ± 8.11
239.01 ± 7.23
203.39 ± 9.97
40% EtOH
219.44 ± 8.12
226.99 ± 8.98
196.78 ± 8.89
50% EtOH
205.78 ± 7.16
218.45 ± 7.89
187.65 ± 8.23
CA-OA
pH 5.8
211.34 ± 3.78
225.67 ± 3.09
154.34 ± 3.34
30% EtOH
208.87 ± 3.22
221.34 ± 3.75
162.56 ± 3.78
40% EtOH
215.45 ± 2.72
231.43 ± 4.29
157.34 ± 4.34
50% EtOH
220.45 ± 4.21
223.56 ± 3.78
163.56 ± 3.86
CA-S-CA
pH 5.8
9.08 ± 1.15
12.01 ± 1.08
17.92 ± 1.64
30% EtOH
—b
3.26 ± 2.78
—
40% EtOH
—
2.13 ± 3.45
—
50% EtOH
—
—
—
Cream
CA
pH 5.8
203.78 ± 7.62
213.76 ± 8.54
164.01 ± 7.89
30% EtOH
210.32 ± 5.23
220.65 ± 7.12
172.55 ± 8.46
40% EtOH
204.56 ± 6.34
199.34 ± 8.67
167.55 ± 4.76
50% EtOH
199.45 ± 6.56
208.64 ± 6.23
158.12 ± 8.22
CA-OA
pH 5.8
177.23 ± 3.41
188.76 ± 2.43
82.65 ± 3.55
30% EtOH
185.33 ± 3.44
190.34 ± 4.21
85.32 ± 2.43
40% EtOH
182.67 ± 2.89
189.52 ± 2.78
90.76 ± 2.87
50% EtOH
180.23 ± 2.34
185.56 ± 3.21
95.16 ± 2.14
CA-S-CA
pH 5.8
—
—
—
30% EtOH
—
—
—
40% EtOH
2.44 ± 1.28
2.13 ± 0.69
—
50% EtOH
3.25 ± 1.33
3.12 ± 1.21
1.61 ± 1.21
a
CA: cellulose acetate; CA-OA: cellulose acetate membrane soaked in oleic acid; CA-S-CA: silicon sheet sandwiched between two cellulose
acetate membranes.
b
Not detectable.
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Table 2. The effect of a change in receptor medium composition and membrane on the release rate of triclosan from a 1 % cream measured
with the 3 diffusion apparatuses
Method
Medium
Franz
Enhancer
Flow-through
Membranea
(µg/cm2/min0.5)
(µg/cm2/min0.5)
(µg/cm2/min0.5))
CA
pH 5.8
2.38 ± 0.61
3.11 ± 0.98
2.06 ± 1.72
30% EtOH
12.41 ± 2.45
17.01 ± 3.09
11.30 ± 3.12
40% EtOH
16.15 ± 3.01
22.41 ± 2.87
14.94 ± 3.65
50% EtOH
20.92 ± 3.22
28.13 ± 3.11
18.62 ± 3.36
CA-OA
pH 5.8
4.12 ± 0.32
5.61 ± 0.24
2.61 ± 0.72
30% EtOH
6.82 ± 0.41
8.01 ± 0.45
3.28 ± 0.81
40% EtOH
8.77 ± 0.62
10.65 ± 0.71
7.57 ± 0.91
50% EtOH
11.45 ± 0.54
14.21 ± 0.41
11.86 ± 0.89
0.98 ± 0.56
—
CA-S-CA
pH 5.8
—b
30% EtOH
2.06 ± 0.23
2.32 ± 0.31
1.72 ± 0.67
40% EtOH
3.12 ± 0.46
3.51 ± 0.32
2.51 ± 0.52
50% EtOH
4.87 ± 0.54
4.65 ± 0.87
4.18 ± 1.21
a
CA: cellulose acetate; CA-OA: cellulose acetate membrane soaked in oleic acid; CA-S-CA: silicon sheet sandwiched between 2 cellulose
acetate membranes.
b
Not detectable.
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Figure 3. Salicylic acid release from a 1% gel measured with a Franz,
Enhancer or flow-through diffusion apparatus using an oleic acid
soaked cellulose acetate membrane and phosphate buffer pH 5.8
(close symbols) or 50% ethanol/buffer mixture (open symbols) as the
dissolution medium.

Figure 4. Salicylic acid release from a 1% cream measured with a
Franz, Enhancer or flow-through diffusion apparatus using an oleic
acid soaked cellulose acetate membrane and phosphate buffer pH 5.8
(close symbols) or 50% ethanol/buffer mixture (open symbols) as the
dissolution medium.

listed in Table 1 and 2 showed that the cellulose acetate
membrane and the cellulose acetate sandwiched silicon gel
sheeting had significantly different permeability characteristics. Since these membranes are either hydrophilic or
lipophilic in nature, they tend to allow the diffusion of
either the salicylic acid or triclosan. Although the release
of salicylic acid and triclosan was slower through the
cellulose acetate membrane soaked in the lipophilic oleic
acid than through just a cellulose acetate membrane the
oleic acid soaked membrane gave more constant and less
variable release rates for both compounds. The results
obtained suggested that although the multi-membrane
system was reported to be a good permeability model for
excised human skin(15), it might not be suitable for routine
quality control evaluation of semisolid products since the
percentage drug release for some products was not
detectable. Release through this multi-layer membrane also
was significantly slower making increasing testing time

beyond what would be reasonable for quality control
testing.
Under all the conditions tested, the release rate of both
salicylic acid and triclosan measured with the flow-through
system was significantly slower than that of the other two
apparatuses. Although the release rates measured with the
Enhancer cell system consistently were slightly higher than
that measured with the Franz cell, these differences were
not significant (f 2 > 50). For each semisolid product,
depending on the selected membrane and medium, the
release of the compounds measured by the 3 methods was
either the same or significantly different. Therefore, it is
essential that the right testing conditions are used to make
valid comparisons. The results in Table 1 and 2 showed
that in this study the oleic acid soaked cellulose acetate
membrane and 2 media, the phosphate buffer pH 5.8 and a
50% ethanol/buffer solution, were the best for comparing
release from the semisolids. Figures 3-5 show the release
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Enhancer or flow-through diffusion apparatus using an oleic acid
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(close symbols) or 50% ethanol/buffer mixture (open symbols) as the
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Figure 6. Comparison of release of hydrocortisone from a 1% cream
measured with the Franz, Enhancer and flow-through methods using
phosphate buffer pH 5.8 or 50% ethanol/buffer mixture as the dissolution medium.

of the 2 compounds when these conditions were used.
From the release profiles, it is also clear that the release of
the water-soluble salicylic acid from the gel was consistently faster than that from the cream, while the release of the
very poorly soluble triclosan was significantly slower than
that of salicylic acid.
II. Release from Cortisone Creams and Ointments
The release rates and profiles for hydrocortisone
(Table 3; Figures 6 and 7) measured by the Enhancer, Franz
and flow-through cell methods depended on formulation
type, concentration of the drug, medium, and apparatus
used. For products containing 0.5% hydrocortisone, release
was not significantly different from the cream and the
ointment, but for both the cream and ointment, the release
was significantly faster in the 50% ethanol/buffer mixture
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Figure 7. Comparison of release of hydrocortisone from a 1%
ointment measured with the Franz, Enhancer and flow-through
methods using phosphate buffer pH 5.8 or 50% ethanol/buffer
mixture as the dissolution medium.

compared to the buffer alone. Increasing the hydrocortisone content from 0.5 to 1% increased the release rate significantly (Figure 6 and 7). In the 50% ethanol/buffer
mixture measured with the Franz and Enhancer cells, the
release from the 1% cream was also significantly faster
than from the ointment. The release rates listed in Table 3
show that the ability of the flow-through cell to measure the
release from semisolids was hampered by the small sample
it can accommodate. Therefore, it was not possible to
measure the release from 0.5% creams and ointments containing hydrocortisone. Comparison of release rates
obtained in this study and release rates available in the literature (Table 3) demonstrated that the conditions used gave
results similar to that obtained independently by other
researchers. Cortisone release results showed that the three
diffusion methods, especially the Franz and Enhancer cells
(Figures 6 and 7) could be used to guide formulation development, to monitor batch-to-batch quality and stability, to
control the manufacturing process, and to demonstrate
equivalency between two similar products.
III. Release from Anti-wrinkle Skin Creams and Gels
As shown by the release rates listed in Table 1 and the
release profiles in Figure 3-5 differences in the dissolution
of salicylic acid from gel and cream could be measured
with the Franz, Enhancer cell and flow-through cells. For
both the cream and the gel f2-values showed that the dissolution rates depended less on the composition of the dissolution medium than on the apparatus used to measure the
release. There was no significant difference in the release
rates measured with the Franz and Enhancer cells.
However, these rates were significantly higher than that
measured with the flow-through cell. Since cortisone
release results showed that the concentration of the active
ingredient in the semisolid can influence the dissolution
rate. The dissolution of salicylic acid from a 0.5, 1, 2 and
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Table 3. Release rates for hydrocortisone from commercially available creams and ointments measured with the Franz, Enhancer, and flowthrough cells
Method
Dosage form
Medium
Franz
Enhancer
Flow-through
(µg/cm2/min0.5)
(µg/cm2/min0.5)
(µg/cm2/min0.5)
0.5 % Cream
pH 5.8
1.27 ± 0.43
1.43 ± 0.42
—a
b
(1.92)
(1.90)
50% EtOH
1.53 ± 0.52
1.89 ± 0.32)
—
(1.93)
(1.91)
0.5% Ointment
pH 5.8
0.86 ± 0.27
1.08 ± 0.28
—
50% EtOH
1.40 ± 0.29
1.84 ± 0.31
—
1.0% Cream
pH 5.8
1.81 ± 0.43
2.17 ± 0.32
2.71 ± 0.31
50% EtOH
3.67 ± 0.62
5.50 ± 0.28
4.29 ± 0.35
(5.02)
(6.29)
1.0% Ointment
pH 5.8
1.38 ± 0.23
1.78 ± 0.24
2.74 ± 0.41
50% EtOH
2.78 ± 0.43
4.30 ± 0.67
3.30 ± 0.78
(2.73)
(3.47)
a
Not detectable.
b
Values listed in brackets were obtained from literature(7,10,12,17,18).
Table 4. Ascorbic acid release rates from a 6 % gel and cream measured with the Franz, Enhancer, and flow-through cells
Method
Dosage form
Medium
Franz
Enhancer
Flow-through
(µg/cm2/min0.5)
(µg/cm2/min0.5)
(µg/cm2/min0.5)
Gel
Buffer pH 5.8
82.37 ± 2.34
83.42 ± 1.89
67.86 ± 4.32
50% EtOH
57.45 ± 3.23
60.12 ± 1.76
48.01 ± 3.32
Cream
Buffer pH 5.8
73.45 ± 2.09
81.34 ± 2.12
56.54 ± 4.32
50% EtOH
66.45 ± 3.11
69.82 ± 1.83
50.23 ± 3.78

300

Release rate (g/cm 2/min 0.5 )

3% cream and gel was measured. The differences in the
release rates are shown in Figure 8. These results show that
release from the gel was significantly faster than from the
cream; that the release rate increased with an increase in
salicylic acid concentration; that the release rates measured
with the Franz and Enhancer cells were significantly faster
than that measured with the flow-through cell; and that the
release profiles obtained with the Franz and Enhancer cell
were similar (f2 > 50).
Another commonly used cosmeceutical ingredient
found in many anti-wrinkle creams is ascorbic acid
(Vitamin C). The release of ascorbic acid from a 6% cream
or gel was measured with the 3 testing methods and the
results were compared. The release rates listed in Table 4
showed that the ascorbic acid release from the gel was significantly faster than from the cream. Also faster release
rates were measured with the Franz and Enhancer cells than
the flow-through cell. Ascorbic acid is very soluble in
water and almost 10 times less soluble in alcohol. This difference in solubility could explain why the release in the
buffer solution was faster than in the 50% ethanol/buffer
mixture.
The results obtained for the water soluble acids
showed that once the data is corrected for differing surface
area release data obtained with the Franz and Enhancer
cells is nearly super-imposable. For these compounds, the
release from both creams and gels measured with the flowthrough cell was always slower than with the other 2
apparatus. Although the more lipophilic oleic acid soaked
cellulose acetate membrane decreased the release rate of
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Figure 8. Scatter-plots showing the release of salicylic acid from
creams containing 0.5 to 3 % salicylic acid, measured with the Franz,
Enhancer and flow-through diffusion cells.
A: cream, Franz cell, pH 5.8; B: cream, Enhancer cell, pH 5.8; C:
cream, flow-through cell, pH 5.8; D: cream, Franz cell, 50% ethanol;
E: cream, Enhancer cell, 50% ethanol; F: cream, flow-through cell,
50% ethanol; G: gel, Franz cell, pH 5.8; H: gel, Enhancer cell, pH
5.8; I: gel, flow-through cell, pH 5.8; J: gel, Franz cell, 50% ethanol;
K: gel, Enhancer cell, 50% ethanol; L: gel, flow-through cell, 50%
ethanol.

these hydrophilic compounds, it increased the consistency
of results. This increased the accuracy of results and the
ability to compare release data. The solubility of the
compounds in the dissolution medium had a significant
effect on the release rates; release was faster in media with
highly soluble compounds. As expected, the release of
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Table 5. Release rates for triclosan and salicylic acid from a combination cream measured with the Franz, Enhancer, and flow-through cells
Method
Ingredient
Medium
Franz
Enhancer
Flow-through
(µg/cm2/min0.5)
(µg/cm2/min0.5)
(µg/cm2/min0.5)
Triclosan (0.1%)
pH 5.8
2.20 ± 0.87
2.75 ± 0.45
1.26 ± 0.56
50% EtOH
5.27 ± 0.67
4.62 ± 0.43
1.49 ± 0.65
Salicylic acid (0.5%)
pH 5.8
84.36 ± 2.86
85.26 ± 2.56
46.93 ± 6.49
50% EtOH
91.06 ± 3.21
88.76 ± 2.45
37.55 ± 7.83

these hydrophilic compounds was faster from gels than
creams. This would make it more difficult to distinguish
between the release rates from semisolids that differ only
slightly in their composition, such as the concentration of
the active ingredient or aqueous/alcohol solubility of the
formulation.
IV. Release from Skin Creams Containing a Bacteriostatic
Agent
Many cosmeceutical products contain more than one
active ingredient. For example, some products contain
multiple alpha hydroxyl acids or alpha hydroxyl acids and a
bacteriostatic agent. This can cause problems when
measuring the release rate especially when there is a huge
difference in the solubility of the 2 compounds. In this
study, the release rates from a combination cream containing 0.1% triclosan and 0.5% salicylic acid were measured.
The release rates are summarized in Table 5. Calculated f2
values showed that the dissolution of triclosan into the
ethanol medium was significantly faster than into the buffer
medium and this difference was largest for the Franz cell (3
µg/cm2/min0.5) and smallest for the flow-through cell (0.2
µg/cm2/min0.5). Due to its higher aqueous solubility the
release of salicylic acid from the cream was significantly
faster than that of triclosan. Release profiles measured with
the Franz and Enhancer cell were similar (f2 > 50) and
although the differences in release rates in the buffer and
ethanol mixture were much smaller, f2-values indicated that
both methods were able to measure this difference. The
flow-through cell was not able to distinguish this difference
because the variations in release profiles were too big, as
shown by the large standard deviations listed in Table 5.
Large variations were caused by the complicated operation
and small sample size used in the flow-through method.
Furthermore, the concentration of the compounds in the dissolution media was very close to the limit of detection for
the analytical methods.

CONCLUSION
Although in vitro release tests were never developed
for bioequivalence testing this study confirmed they can be
used to assess the “sameness” of products during quality
testing, formulation development, scale-up or postmarketing formulation and manufacturing changes. The
results presented also showed that the Franz, Enhancer, and

flow-through cells can be used for these purposes to test
cosmeceutical semisolids containing hydrophilic and
lipophilic active ingredients if appropriate dissolution
medium and membrane are used. The main advantages of
the Franz and Enhancer cells over the flow-through cells
are the ease of operation and larger sample sizes ensuring
more consistent results. Although the Franz and Enhancer
cells gave similar release results for the products tested in
this study, the advantages of the Enhancer cells are that
they used the basic USP dissolution apparatus and had a
larger volume range, making it easier to adapt the system to
study the release of products containing low concentrations
of active ingredients or ingredients that are difficult to
analyze.
In the future, if regulatory agencies require more
stringent testing of cosmeceutical products, it is hoped that
the results presented in this paper will help to show that
similar to the dissolution testing of oral dosage forms, in
vitro release testing with diffusion cells offer a simple,
reliable, reproducible quality control test that can be used to
monitor the quality and stability of semisolid cosmetic
products.
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